MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy-Reference-Cited by-同舟云学术

MET Expression in Advanced Non–Small-Cell Lung Cancer: Effect on Clinical Outcomes of Chemotherapy, Targeted Therapy, and Immunotherapy

Published:2018-07 Issue:4 Volume:19 Page:e441-e463
ISSN:1525-7304
Container-title:Clinical Lung Cancer
language:en
Short-container-title:Clinical Lung Cancer

Author:

Reis Henning,Metzenmacher Martin,Goetz Moritz,Savvidou Nikoleta,Darwiche Kaid,Aigner Clemens,Herold Thomas,Eberhardt Wilfried E.,Skiba Charlotte,Hense Jörg,Virchow Isabel,Westerwick Daniela,Bogner Simon,Ting Saskia,Kasper Stefan,Stuschke Martin,Nensa Felix,Herrmann Ken,Hager Thomas,Schmid Kurt W.,Schuler Martin,Wiesweg Marcel

Funder

Deutsche Krebshilfe

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference53 articles.

1. The Met receptor tyrosine kinase: a key player in oncogenesis and drug resistance;Maroun;Pharmacol Ther,2014

2. MET signalling: principles and functions in development, organ regeneration and cancer;Trusolino;Nat Rev Mol Cell Biol,2010

3. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion;Ma;Br J Cancer,2007

4. An overview of the c-MET signaling pathway;Organ;Ther Adv Med Oncol,2011

5. Clinicopathological significance and concordance analysis of c-MET immunohistochemistry in non–small-cell lung cancers: a meta-analysis;Pyo;Pathol Res Pract,2016

Cited by 64 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cancer Patient-Derived Cell-Based Models: Applications and Challenges in Functional Precision Medicine;Life;2024-09-10

2. Novel molecular subtypes of METex14 non-small cell lung cancer with distinct biological and clinical significance;npj Precision Oncology;2024-07-26

3. Capmatinib plus nivolumab in pretreated patients with EGFR wild-type advanced non–small cell lung cancer;Lung Cancer;2024-06

4. Prognostic and predictive biomarkers with therapeutic targets in nonsmall-cell lung cancer: A 2023 update on current development, evidence, and recommendation;Journal of Oncology Pharmacy Practice;2024-04-05

5. First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations;European Journal of Cancer;2024-03